HASBROUCK HEIGHTS, N.J., May 4, 2011 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (Nasdaq:NYMX) provided a further update today on the Company's ongoing Phase 3 trials (NX02-0017 and NX02-0018) for NX-1207, Nymox's investigational drug for benign prostatic hyperplasia (BPH). The Safety Monitoring Committee meeting of May 3, 2011 found no significant safety concerns to date for the two pivotal U.S. trials being conducted at over 70 urology clinical research sites across the U.S.
